U.S. Markets open in 6 hrs 27 mins

Peregrine Pharmaceuticals, Inc. (PPHM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.62+0.01 (+1.82%)
At close: 4:00PM EDT
People also watch
  • Is IHump's Spanky saying King bought 20 million shares? "King... 20m shares at $0.27".
  • When is this POS company going to to finally announce its RS?
  • PPHM is a scam. I got paid $100 for posts on iHub with my 8 different accounts
  • 3 more days w/ no posts. It's tough to write anything worthwhile about an anemic stock like PPHM.
    How DO those I-Humpers do it?
    I guess some will do about anything - no matter how mundane - for a paycheck.
  • AXSM (MC $85 M)(Cash $60 M) 5x BIG Phase 3 in various indications targeting large Markets with first results in Q3 2017 = 2000% POTENTIAL..UNKNOWN low float Stock !!! A BIG LIFETIME OPPORTUNITY GUYS ! GLTA

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $60 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $60.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • I don't see the executives buying many shares in the open market, or by exercising options. So, what's the concern with the options these guys are issued? Seems like they must just expire worthless.

    "Over the course of employment, a company generally issues ESOs to an employee which can be exercised at a particular price set on the grant day, generally the company's current stock price. Depending on the vesting schedule and the maturity of the options, the employee may elect to exercise the options at some point, obligating the company to sell the employee its stock at whatever stock price was used as the exercise price. At that point, the employee may either sell the stock, or hold on to it in the hope of further price appreciation or hedge the stock position with listed calls and puts. The employee may also hedge the employee stock options prior to exercise with exchange traded calls and puts and avoid forfeiture of a major part of the options value back to the company thereby reducing risks and delaying taxes."
  • Insiders buying got the info today. Get ready for a huge breakout, so says the street signs. They took out all the dumb investors stops. Now she goes. Have a nice day.
  • Well looks like they had to have filed the appeal or we would have done the RS. Still the stock needs better then a 50% move to get over $1. Hopefully some partner for Exosome or BAVI. At least we have something though far from being anything more then a bunch of promises.
  • Time is of the essence (I know, can't mean PP, can it)? PP July 23, 2008 PR: "The NASDAQ Staff Determination letter states that historically, Panels have generally viewed a reverse stock split implemented within 30 to 60 days as the only definitive plan acceptable to resolve a bid price deficiency..."
  • Same #$%$ different day. Price action is nice and maybe somebody knows something on the RS? We should know today or tomorrow at the latest. I would think an appeal would be a material event and would have to be shown in an 8K? Thumpers all pumping and you would think we were already at $1. IMO not enough volume to matter as we trade less then $1M in stock. Well now that Bavi will cure everything including Grubbs in your lawn I guess its time to buy. I'm sitting and waiting with my shares and hoping for the best. If they announce the RS I'm out the door. BOD should all be fired if they have to RS along with SK.
  • the vile and deviant stock shorter, CloakedProPredator, slithering his way back into IO-Hump's den of thieves with seemingly unending paragraphs trying to explain away the unexplainable. . So many paragraphs he is bound to contradict his own lies at some point and again he has today. . But that's OK. . Right, humpers?
  • I expected a similar PR today. Maybe tomorrow -
    July 23, 2008
    Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
    - Company Will Request Hearing to Present Plans for Regaining Compliance -
    - NASDAQ Hearing Panel Has Discretion to Grant Peregrine Up to an Additional 180 Days to Regain Compliance -
    - Peregrine Currently Meets All Other NASDAQ Capital Market Initial Listing Requirements Other Than the $1.00 Minimum Bid Price Rule -

    TUSTIN, Calif., July 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July 22, 2008 indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4). As a result, the company's common stock would be subject to delisting from the NASDAQ Capital Market unless Peregrine requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"). Peregrine intends to request a hearing before the Panel, which will stay the delisting of the company's securities pending the Panel's decision. Rule 4805(a) provides that all hearings shall be scheduled, to the extent practicable, within 45 days of the date that the request for hearing is filed.

    At the hearing, Peregrine intends to request continued listing on the NASDAQ Capital Market based upon its plan for regaining compliance with the minimum bid price requirement. Pursuant to NASDAQ Marketplace Rule 4802(b), the Panel has the authority to grant Peregrine up to an additional 180 days from the date of the Staff Determination letter of July 22, 2008 (i.e. January 19, 2009) to implement its plan of compliance, which could include a reverse stock split if the price has not exceeded $1.00 per share for 10 consecutive business days by that time.

    The NASDAQ Staff Determination letter states that historically, Panels have generally viewed a reverse stock split implemented within 30 to 60 days as the only definitive plan acceptable to resolve a bid price deficiency, but that recently the authority of Panels to grant additional time to companies was modified so that a Panel could allow up to 180 calendar days from the date of the Staff Determination letter, if the Panel deems it appropriate. The letter notes that the company may wish to consider presenting a plan that includes a discussion of the events that it believes will enable it to regain compliance in this time frame and a commitment to effect a reverse stock split, if necessary. However, there can be no assurance that the Panel will grant Peregrine's request for continued listing on the NASDAQ Capital Market.

    As announced on July 25, 2007, Peregrine received a letter from NASDAQ advising that the bid price of the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 4310(c)(4) for the previous 30 consecutive business days. In accordance with NASDAQ Marketplace Rule 4310(c)(4), the company was provided 180 calendar days and granted an additional 180-day-extension period, or until July 21, 2008, to regain compliance with the minimum bid price requirement.
  • The day has arrived. PR after close? But from PP or NASDAQ?

    Letter from NASDAQ on Apr 11: "The letter further states that the Staff has determined to delist the Company’s securities, both common and preferred stock, from the NASDAQ Capital Market on April 20, 2017, unless the Company requests a hearing before the NASDAQ Hearings Panel (the “Panel”) by April 18, 2017 to appeal the Staff’s determination to delist its securities."
  • Funny. Humpers have their undies all in a bunch over what they call "fake news" from Reuters in how they report Ronin's PPHM holdings.
    Of course the decades of obvious FAKE NEWS by the resident scam running pumper/dumpers is just Okie-Dokie though
  • Will PP make a run for the Russell this year? Reverse split would be a good start. Get up there to $5. Time running out, though.
  • No PR? In 2008 the delisting filing and PR were released on the same day.
  • King of Pain looks ready to hit the ground running again. I can almost smell those fresh authorized shares.
  • Is wook the reason Target went to transgender bathrooms?
    He's getting more creepily unbearable than normal.
  • For more PP color (Pink? LOL) you might tune in: Carlsbad, California, March 15, 2017 (GLOBE NEWSWIRE) -- Patriot Scientific Corporation (OTC PINK: PTSC) today announced that its Annual Meeting of Stockholders will be held on May 4, 2017. The meeting will be conducted in a virtual format and broadcast via web streaming. Additional details regarding the meeting are available in the Company’s Definitive Proxy Statement as filed today with the Securities and Exchange Commission.
  • Looks like the drip towards the exit before the reverse split is becoming a gusher. That took longer than I thought but with Good Friday Holiday coming people don't want to be caught with money on the table if/when the reverse split is announced over the long weekend.